EZH2 and chronic myelomonocytic leukemia: With NGS technologies being more accessible each day, we would recommend to perform targeted molecular analysis of ASXL1 and, if possible, EZH2, NRAS, SRSF2 and TET2 in patients with CMML and low risk cytogenetic features or uninformative CC.